

# Shyam Sundar

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2388927/shyam-sundar-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

262  
papers

15,086  
citations

61  
h-index

115  
g-index

270  
ext. papers

17,198  
ext. citations

6.7  
avg, IF

6.74  
L-index

| #   | Paper  | IF   | Citations |
|-----|--|------|-----------|
| 262 | An In-depth Proteomic Map of Leishmania donovani Isolate from Post Kala-azar Dermal Leishmaniasis (PKDL) Patient.. <i>Acta Parasitologica</i> , <b>2022</b> , 1  | 1.7  |           |
| 261 | Emerging role of $\text{CD}4^+$ cells in protozoan infection and their potential clinical application.. <i>Infection, Genetics and Evolution</i> , <b>2022</b> , 98, 105210  | 4.5  | 1         |
| 260 | Carboxymethyl chitosan modified lipid nanoformulations as a highly efficacious and biocompatible oral anti-leishmanial drug carrier system.. <i>International Journal of Biological Macromolecules</i> , <b>2022</b> , 204, 373-385                | 7.9  | 3         |
| 259 | Febrifugine dihydrochloride as a new oral chemotherapeutic agent against visceral leishmaniasis infection.. <i>Experimental Parasitology</i> , <b>2022</b> , 108250  | 2.1  |           |
| 258 | A Novel Bioimpedance-Based Detection of Miltefosine Susceptibility Among Clinical Isolates of the Indian Subcontinent Exhibiting Resistance to Multiple Drugs.. <i>Frontiers in Cellular and Infection Microbiology</i> , <b>2021</b> , 11, 768830 | 5.9  | 1         |
| 257 | An Insight Into Systemic Immune Response in Mediated Atypical Cutaneous Leishmaniasis in the New Endemic State of Himachal Pradesh, India.. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 765684  | 8.4  | 1         |
| 256 | Amphiregulin in cellular physiology, health, and disease: Potential use as a biomarker and therapeutic target. <i>Journal of Cellular Physiology</i> , <b>2021</b> ,   | 7    | 2         |
| 255 | Assessing Skin Parasite Load: A Proof of Concept Study of a Microbiopsy Device in an Indian Setting. <i>Frontiers in Cellular and Infection Microbiology</i> , <b>2021</b> , 11, 645121  | 5.9  | 3         |
| 254 | Domestic mammals as reservoirs for Leishmania donovani on the Indian subcontinent: Possibility and consequences on elimination. <i>Transboundary and Emerging Diseases</i> , <b>2021</b> ,   | 4.2  | 5         |
| 253 | Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients. <i>Clinical Pharmacokinetics</i> , <b>2021</b> , 60, 1463-1473                  | 6.2  | 3         |
| 252 | Anti-Interleukin-10 Unleashes Transcriptional Response to Leishmanial Antigens in Visceral Leishmaniasis Patients. <i>Journal of Infectious Diseases</i> , <b>2021</b> , 223, 517-521  | 7    | 2         |
| 251 | IFN- $\gamma$ /CD4T cell-driven prophylactic potential of recombinant LDBPK_252400 hypothetical protein of Leishmania donovani against visceral leishmaniasis. <i>Cellular Immunology</i> , <b>2021</b> , 361, 104272                              | 4.4  | 2         |
| 250 | The drug resistance mechanisms in Leishmania donovani are independent of immunosuppression. <i>Cytokine</i> , <b>2021</b> , 145, 155300  | 4    | 1         |
| 249 | Nanodiagnosics in leishmaniasis: A new frontiers for early elimination. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , <b>2021</b> , 13, e1675   | 9.2  | 3         |
| 248 | Mutations in an Aquaglyceroporin as a Proven Marker of Antimony Clinical Resistance in the Parasite Leishmania donovani. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 72, e526-e532   | 11.6 | 6         |
| 247 | Xenodiagnosis to evaluate the infectiousness of humans to sandflies in an area endemic for visceral leishmaniasis in Bihar, India: a transmission-dynamics study. <i>Lancet Microbe, The</i> , <b>2021</b> , 2, e23-e31                            | 22.2 | 19        |
| 246 | Herbal Medicines for Thyroid Diseases. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , <b>2021</b> , 256-277.  | 2    |           |

|     |   |      |    |
|-----|---|------|----|
| 245 | Utility of Blood as the Clinical Specimen for the Molecular Diagnosis of Post-Kala-Azar Dermal Leishmaniasis. <i>Journal of Clinical Microbiology</i> , <b>2021</b> , 59, e0013221  | 9.7  | 0  |
| 244 | SWATH-MS based quantitative proteomics analysis to evaluate the antileishmanial effect of Commiphora wightii- Guggul and Amphotericin B on a clinical isolate of Leishmania donovani. <i>Journal of Proteomics</i> , <b>2020</b> , 223, 103800                                  | 3.9  | 5  |
| 243 | Post kala-azar dermal leishmaniasis: A threat to elimination program. <i>PLoS Neglected Tropical Diseases</i> , <b>2020</b> , 14, e0008221  | 4.8  | 18 |
| 242 | Evaluation of Safety and Antileishmanial Efficacy of Amine Functionalized Carbon-Based Composite Nanoparticle Appended With Amphotericin B: An and Preclinical Study. <i>Frontiers in Chemistry</i> , <b>2020</b> , 8, 510  | 5    | 10 |
| 241 | Improving anti-leishmanial activity of amphotericin B and paromomycin using co-delivery in d- $\alpha$ -tocopheryl polyethylene glycol 1000 succinate (TPGS) tailored nano-lipid carrier system. <i>Chemistry and Physics of Lipids</i> , <b>2020</b> , 231, 104946             | 3.7  | 5  |
| 240 | MicroRNA exporter HuR clears the internalized pathogens by promoting pro-inflammatory response in infected macrophages. <i>EMBO Molecular Medicine</i> , <b>2020</b> , 12, e11011   | 12   | 10 |
| 239 | Type I Interferons Suppress Anti-parasitic Immunity and Can Be Targeted to Improve Treatment of Visceral Leishmaniasis. <i>Cell Reports</i> , <b>2020</b> , 30, 2512-2525.e9  | 10.6 | 21 |
| 238 | Male predominance in reported Visceral Leishmaniasis cases: Nature or nurture? A comparison of population-based with health facility-reported data. <i>PLoS Neglected Tropical Diseases</i> , <b>2020</b> , 14, e0007995  | 4.8  | 12 |
| 237 | Setting Our Sights on Infectious Diseases. <i>ACS Infectious Diseases</i> , <b>2020</b> , 6, 3-13   | 5.5  | 9  |
| 236 | Formulation, characterization and in vitro anti-leishmanial evaluation of amphotericin B loaded solid lipid nanoparticles coated with vitamin B-stearic acid conjugate. <i>Materials Science and Engineering C</i> , <b>2020</b> , 117, 111279                                  | 8.3  | 12 |
| 235 | Short-Course Treatment With Imipramine Entrapped in Squalene Liposomes Results in Sterile Cure of Experimental Visceral Leishmaniasis Induced by Antimony Resistant With Increased Efficacy. <i>Frontiers in Cellular and Infection Microbiology</i> , <b>2020</b> , 10, 595415 | 5.9  | 2  |
| 234 | Recuperating Biopharmaceutical Aspects of Amphotericin B and Paromomycin Using a Chitosan Functionalized Nanocarrier via Oral Route for Enhanced Anti-leishmanial Activity. <i>Frontiers in Cellular and Infection Microbiology</i> , <b>2020</b> , 10, 570573                  | 5.9  | 7  |
| 233 | Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis. <i>Scientific Reports</i> , <b>2020</b> , 10, 12243  | 4.9  | 26 |
| 232 | Sensible graphene oxide differentiates macrophages and : a bio-nano interplay in attenuating intracellular parasite.. <i>RSC Advances</i> , <b>2020</b> , 10, 27502-27511   | 3.7  | 4  |
| 231 | Xenodiagnosis to address key questions in visceral leishmaniasis control and elimination. <i>PLoS Neglected Tropical Diseases</i> , <b>2020</b> , 14, e0008363  | 4.8  | 13 |
| 230 | The NK cell granule protein NKG7 regulates cytotoxic granule exocytosis and inflammation. <i>Nature Immunology</i> , <b>2020</b> , 21, 1205-1218  | 19.1 | 24 |
| 229 | Isolation and characterisation of Leishmania donovani protein antigens from urine of visceral leishmaniasis patients. <i>PLoS ONE</i> , <b>2020</b> , 15, e0238840  | 3.7  | 1  |
| 228 | IL-10 and TGF- $\beta$ -Induced Arginase Expression Contributes to Deficient Nitric Oxide Response in Human Visceral Leishmaniasis. <i>Frontiers in Cellular and Infection Microbiology</i> , <b>2020</b> , 10, 614165  | 5.9  | 3  |

|     |  |     |    |
|-----|--|-----|----|
| 227 | A molecular signature for CD8 T cells from visceral leishmaniasis patients. <i>Parasite Immunology</i> , <b>2019</b> , 41, e12669  | 2.2 | 6  |
| 226 | Meta-taxonomic analysis of prokaryotic and eukaryotic gut flora in stool samples from visceral leishmaniasis cases and endemic controls in Bihar State India. <i>PLoS Neglected Tropical Diseases</i> , <b>2019</b> , 13, e0007444 | 4.8 | 16 |
| 225 | Refining wet lab experiments with in silico searches: A rational quest for diagnostic peptides in visceral leishmaniasis. <i>PLoS Neglected Tropical Diseases</i> , <b>2019</b> , 13, e0007353                                     | 4.8 | 2  |
| 224 | Exploiting knowledge on pharmacodynamics-pharmacokinetics for accelerated anti-leishmanial drug discovery/development. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2019</b> , 15, 595-612                         | 5.5 | 1  |
| 223 | Current and emerging medications for the treatment of leishmaniasis. <i>Expert Opinion on Pharmacotherapy</i> , <b>2019</b> , 20, 1251-1265  | 4   | 63 |
| 222 | Iron superoxide dismutase contributes to miltefosine resistance in <i>Leishmania donovani</i> . <i>FEBS Journal</i> , <b>2019</b> , 286, 3488-3503   | 5.7 | 18 |
| 221 | Immunogenicity and Protective Efficacy of T-Cell Epitopes Derived From Potential Th1 Stimulatory Proteins of. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 288   | 8.4 | 13 |
| 220 | Therapeutic Leishmaniasis: Recent Advancement and Developments in Nanomedicines <b>2019</b> , 195-220  |     | 3  |
| 219 | Determinants for progression from asymptomatic infection to symptomatic visceral leishmaniasis: A cohort study. <i>PLoS Neglected Tropical Diseases</i> , <b>2019</b> , 13, e0007216   | 4.8 | 28 |
| 218 | Development of a Multiplexed Assay for Detection of and Protein Biomarkers in Urine Samples of Patients with Visceral Leishmaniasis. <i>Journal of Clinical Microbiology</i> , <b>2019</b> , 57,                                   | 9.7 | 9  |
| 217 | Interleukin 2 is an Upstream Regulator of CD4+ T Cells From Visceral Leishmaniasis Patients With Therapeutic Potential. <i>Journal of Infectious Diseases</i> , <b>2019</b> , 220, 163-173   | 7   | 5  |
| 216 | Transcriptional blood signatures for active and amphotericin B treated visceral leishmaniasis in India. <i>PLoS Neglected Tropical Diseases</i> , <b>2019</b> , 13, e0007673   | 4.8 | 11 |
| 215 | Envisioning the innovations in nanomedicine to combat visceral leishmaniasis: for future theranostic application. <i>Nanomedicine</i> , <b>2019</b> , 14, 1911-1927  | 5.6 | 16 |
| 214 | Post kala azar dermal leishmaniasis and leprosy prevalence and distribution in the Muzaffarpur health and demographic surveillance site. <i>PLoS Neglected Tropical Diseases</i> , <b>2019</b> , 13, e0007798                      | 4.8 | 6  |
| 213 | Human Papillomavirus Genome based Detection and Typing: A Holistic Molecular Approach. <i>Current Molecular Medicine</i> , <b>2019</b> , 19, 237-246   | 2.5 | 6  |
| 212 | Abnormal B-Cell Subset and Blimp-1-Mediated Humoral Responses Associated With Visceral Leishmaniasis Pathogenesis. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2019</b> , 100, 816-821                           | 3.2 | 4  |
| 211 | Effectiveness of Single-Dose Liposomal Amphotericin B in Visceral Leishmaniasis in Bihar. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2019</b> , 101, 795-798  | 3.2 | 5  |
| 210 | <i>Leishmania donovani</i> evades Caspase 1 dependent host defense mechanism during infection. <i>International Journal of Biological Macromolecules</i> , <b>2019</b> , 126, 392-401  | 7.9 | 8  |

|     |   |      |    |
|-----|---|------|----|
| 209 | Detection of Immunoglobulin G1 Against rK39 Improves Monitoring of Treatment Outcomes in Visceral Leishmaniasis. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 69, 1130-1135  | 11.6 | 14 |
| 208 | HLA-DR Class II expression on myeloid and lymphoid cells in relation to HLA-DRB1 as a genetic risk factor for visceral leishmaniasis. <i>Immunology</i> , <b>2019</b> , 156, 174-186  | 7.8  | 3  |
| 207 | Hepcidin mediated iron homoeostasis as immune regulator in visceral leishmaniasis patients. <i>Parasite Immunology</i> , <b>2019</b> , 41, e12601   | 2.2  | 4  |
| 206 | Leishmaniasis: treatment, drug resistance and emerging therapies. <i>Expert Opinion on Orphan Drugs</i> , <b>2019</b> , 7, 1-10   | 1.1  | 21 |
| 205 | Post kala azar dermal leishmaniasis and leprosy prevalence and distribution in the Muzaffarpur health and demographic surveillance site <b>2019</b> , 13, e0007798  |      |    |
| 204 | Post kala azar dermal leishmaniasis and leprosy prevalence and distribution in the Muzaffarpur health and demographic surveillance site <b>2019</b> , 13, e0007798  |      |    |
| 203 | Post kala azar dermal leishmaniasis and leprosy prevalence and distribution in the Muzaffarpur health and demographic surveillance site <b>2019</b> , 13, e0007798  |      |    |
| 202 | Post kala azar dermal leishmaniasis and leprosy prevalence and distribution in the Muzaffarpur health and demographic surveillance site <b>2019</b> , 13, e0007798  |      |    |
| 201 | Epitope-Binding Characteristics for Risk versus Protective DRB1 Alleles for Visceral Leishmaniasis. <i>Journal of Immunology</i> , <b>2018</b> , 200, 2727-2737   | 5.3  | 9  |
| 200 | Visceral Leishmaniasis-Optimum Treatment Options in Children. <i>Pediatric Infectious Disease Journal</i> , <b>2018</b> , 37, 492-494   | 3.4  | 11 |
| 199 | Mannose-conjugated curcumin-chitosan nanoparticles: Efficacy and toxicity assessments against <i>Leishmania donovani</i> . <i>International Journal of Biological Macromolecules</i> , <b>2018</b> , 111, 109-120   | 7.9  | 34 |
| 198 | Emerging therapeutic targets for treatment of leishmaniasis. <i>Expert Opinion on Therapeutic Targets</i> , <b>2018</b> , 22, 467-486   | 6.4  | 28 |
| 197 | Understanding <i>Leishmania</i> parasites through proteomics and implications for the clinic. <i>Expert Review of Proteomics</i> , <b>2018</b> , 15, 371-390  | 4.2  | 12 |
| 196 | Molecular, biochemical characterization and assessment of immunogenic potential of cofactor-independent phosphoglycerate mutase against <i>Leishmania donovani</i> : a step towards exploring novel vaccine candidate. <i>Parasitology</i> , <b>2018</b> , 145, 508-526 | 2.7  | 2  |
| 195 | Functional Involvement of <i>Leishmania donovani</i> Tryparedoxin Peroxidases during Infection and Drug Treatment. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2018</b> , 62,   | 5.9  | 11 |
| 194 | Peripheral Blood Monocytes With an Antiinflammatory Phenotype Display Limited Phagocytosis and Oxidative Burst in Patients With Visceral Leishmaniasis. <i>Journal of Infectious Diseases</i> , <b>2018</b> , 218, 1130-1141  | 7    | 12 |
| 193 | Combined neutralization of interferon gamma and tumor necrosis factor alpha induces IL-4 production but has no direct additive impact on parasite burden in splenic cultures of human visceral leishmaniasis. <i>PLoS ONE</i> , <b>2018</b> , 13, e0199817              | 3.7  | 4  |
| 192 | Identification and Functional Validation of a Biomarker for the Diagnosis of Miltefosine Relapse during Visceral Leishmaniasis. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2018</b> , 98, 492-496  | 3.2  | 2  |

|     |  |     |    |
|-----|--|-----|----|
| 191 | Visceral Leishmaniasis in the Muzaffapur Demographic Surveillance Site: A Spatiotemporal Analysis. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2018</b> , 99, 1555-1561  | 3.2 | 7  |
| 190 | Molecular Diagnosis of Visceral Leishmaniasis. <i>Molecular Diagnosis and Therapy</i> , <b>2018</b> , 22, 443-457  | 4.5 | 52 |
| 189 | Chemotherapeutics of visceral leishmaniasis: present and future developments. <i>Parasitology</i> , <b>2018</b> , 145, 481-489   | 2.7 | 65 |
| 188 | Validation of SYBR green I based closed tube loop mediated isothermal amplification (LAMP) assay and simplified direct-blood-lysis (DBL)-LAMP assay for diagnosis of visceral leishmaniasis (VL). <i>PLoS Neglected Tropical Diseases</i> , <b>2018</b> , 12, e0006922                   | 4.8 | 22 |
| 187 | Visceral Leishmaniasis IgG1 Rapid Monitoring of Cure vs. Relapse, and Potential for Diagnosis of Post Kala-Azar Dermal Leishmaniasis. <i>Frontiers in Cellular and Infection Microbiology</i> , <b>2018</b> , 8, 427   | 5.9 | 16 |
| 186 | Human papillomavirus infection & anal cytological abnormalities in HIV-positive men in eastern India. <i>BMC Infectious Diseases</i> , <b>2018</b> , 18, 692   | 4   | 2  |
| 185 | Visceral leishmaniasis: Spatiotemporal heterogeneity and drivers underlying the hotspots in Muzaffarpur, Bihar, India. <i>PLoS Neglected Tropical Diseases</i> , <b>2018</b> , 12, e0006888  | 4.8 | 22 |
| 184 | Visceral leishmaniasis elimination targets in India, strategies for preventing resurgence. <i>Expert Review of Anti-Infective Therapy</i> , <b>2018</b> , 16, 805-812  | 5.5 | 30 |
| 183 | Febrifugine analogues as Leishmania donovani trypanothione reductase inhibitors: binding energy analysis assisted by molecular docking, ADMET and molecular dynamics simulation. <i>Journal of Biomolecular Structure and Dynamics</i> , <b>2017</b> , 35, 141-158                       | 3.6 | 41 |
| 182 | Particle induced X-ray emission study of blood samples of Indian Kala-azar patients. <i>Journal of Parasitic Diseases</i> , <b>2017</b> , 41, 193-198  | 1.3 | 3  |
| 181 | Structure-based virtual screening, molecular docking, ADMET and molecular simulations to develop benzoxaborole analogs as potential inhibitor against Leishmania donovani trypanothione reductase. <i>Journal of Receptor and Signal Transduction Research</i> , <b>2017</b> , 37, 60-70 | 2.6 | 33 |
| 180 | Inflammatory chemokines and their receptors in human visceral leishmaniasis: Gene expression profile in peripheral blood, splenic cellular sources and their impact on trafficking of inflammatory cells. <i>Molecular Immunology</i> , <b>2017</b> , 85, 111-119                        | 4.3 | 12 |
| 179 | Integrating genomics and proteomics permits identification of immunodominant antigens associated with drug resistance in human visceral leishmaniasis in India. <i>Experimental Parasitology</i> , <b>2017</b> , 176, 30-45  | 2.1 | 4  |
| 178 | Voacamine alters Leishmania ultrastructure and kills parasite by poisoning unusual bi-subunit topoisomerase IB. <i>Biochemical Pharmacology</i> , <b>2017</b> , 138, 19-30   | 6   | 18 |
| 177 | Transcriptome profiling identifies genes/pathways associated with experimental resistance to paromomycin in Leishmania donovani. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , <b>2017</b> , 7, 370-377   | 4   | 11 |
| 176 | Investments in Research and Surveillance Are Needed to Go Beyond Elimination and Stop Transmission of Leishmania in the Indian Subcontinent. <i>PLoS Neglected Tropical Diseases</i> , <b>2017</b> , 11, e00051190   | 4.8 | 20 |
| 175 | Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stress. <i>PLoS Neglected Tropical Diseases</i> , <b>2017</b> , 11, e0005641                                 | 4.8 | 46 |
| 174 | The Phenotype of Circulating Neutrophils during Visceral Leishmaniasis. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2017</b> , 97, 767-770   | 3.2 | 10 |

|     |   |      |     |
|-----|---|------|-----|
| 173 | Leptomonas seymouri narna-like virus 1 and not leishmaniviruses detected in kala-azar samples from India. <i>Archives of Virology</i> , <b>2017</b> , 162, 3827-3835  | 2.6  | 14  |
| 172 | Interventions for visceral leishmaniasis. <i>The Cochrane Library</i> , <b>2017</b> ,   | 5.2  | 78  |
| 171 | Wnt5a Signaling Promotes Host Defense against Infection. <i>Journal of Immunology</i> , <b>2017</b> , 199, 992-1002   | 5.3  | 14  |
| 170 | Phenotypic and functional characteristics of HLA-DR neutrophils in Brazilians with cutaneous leishmaniasis. <i>Journal of Leukocyte Biology</i> , <b>2017</b> , 101, 739-749  | 6.5  | 17  |
| 169 | Establishing, Expanding, and Certifying a Closed Colony of Phlebotomus argentipes (Diptera: Psychodidae) for Xenodiagnostic Studies at the Kala Azar Medical Research Center, Muzaffarpur, Bihar, India. <i>Journal of Medical Entomology</i> , <b>2017</b> , 54, 1129-1139 | 2.2  | 13  |
| 168 | Immune Checkpoint Targets for Host-Directed Therapy to Prevent and Treat Leishmaniasis. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 1492  | 8.4  | 24  |
| 167 | Alcoholic Fractions F5 and F6 from Leaves Show a Potent Antileishmanial and Immunomodulatory Activities to Control Experimental Visceral Leishmaniasis. <i>Frontiers in Medicine</i> , <b>2017</b> , 4, 55  | 4.9  | 11  |
| 166 | Clinical Abacavir Hypersensitivity Reaction among Children in India. <i>Indian Journal of Pediatrics</i> , <b>2016</b> , 83, 855-8  | 3    | 5   |
| 165 | High-throughput virtual screening and quantum mechanics approach to develop imipramine analogues as leads against trypanothione reductase of leishmania. <i>Biomedicine and Pharmacotherapy</i> , <b>2016</b> , 83, 141-152   | 7.5  | 32  |
| 164 | Recent developments and future prospects in the treatment of visceral leishmaniasis. <i>Therapeutic Advances in Infectious Disease</i> , <b>2016</b> , 3, 98-109  | 2.8  | 80  |
| 163 | Understanding the transmission dynamics of Leishmania donovani to provide robust evidence for interventions to eliminate visceral leishmaniasis in Bihar, India. <i>Parasites and Vectors</i> , <b>2016</b> , 9, 25   | 4    | 47  |
| 162 | Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective. <i>Infectious Diseases of Poverty</i> , <b>2016</b> , 5, 19   | 10.4 | 100 |
| 161 | Suppression of host PTEN gene expression for Leishmania donovani survival in Indian visceral leishmaniasis. <i>Microbes and Infection</i> , <b>2016</b> , 18, 369-72  | 9.3  | 2   |
| 160 | Exploring the inhibitory activity of Withaferin-A against Pteridine reductase-1 of L. donovani. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , <b>2016</b> , 31, 1029-37   | 5.6  | 8   |
| 159 | Blimp-1-Dependent IL-10 Production by Tr1 Cells Regulates TNF-Mediated Tissue Pathology. <i>PLoS Pathogens</i> , <b>2016</b> , 12, e1005398   | 7.6  | 57  |
| 158 | Why do Patients in Pre-Anti Retroviral Therapy (ART) Care Default: A Cross-Sectional Study. <i>Indian Journal of Community Medicine</i> , <b>2016</b> , 41, 241-4   | 0.8  | 6   |
| 157 | Evolutionary genomics of epidemic visceral leishmaniasis in the Indian subcontinent. <i>ELife</i> , <b>2016</b> , 5,  | 8.9  | 107 |
| 156 | -Induced Increase in Macrophage Bcl-2 Favors Parasite Survival. <i>Frontiers in Immunology</i> , <b>2016</b> , 7, 456   | 8.4  | 15  |

|     |  |      |     |
|-----|--|------|-----|
| 155 | Differential Expression of miRNA Regulates T Cell Differentiation and Plasticity During Visceral Leishmaniasis Infection. <i>Frontiers in Microbiology</i> , <b>2016</b> , 7, 206  | 5.7  | 49  |
| 154 | Comparative Analysis of Cellular Immune Responses in Treated Leishmania Patients and Hamsters against Recombinant Th1 Stimulatory Proteins of Leishmania donovani. <i>Frontiers in Microbiology</i> , <b>2016</b> , 7, 312   | 5.7  | 10  |
| 153 | Tumor necrosis factor alpha neutralization has no direct effect on parasite burden, but causes impaired IFN- $\gamma$ production by spleen cells from human visceral leishmaniasis patients. <i>Cytokine</i> , <b>2016</b> , 85, 184-90  | 4    | 8   |
| 152 | A Subset of Neutrophils Expressing Markers of Antigen-Presenting Cells in Human Visceral Leishmaniasis. <i>Journal of Infectious Diseases</i> , <b>2016</b> , 214, 1531-1538   | 7    | 21  |
| 151 | Recombinant Leishmania Rab6 (rLdRab6) is recognized by sera from visceral leishmaniasis patients. <i>Experimental Parasitology</i> , <b>2016</b> , 170, 135-147  | 2.1  | 6   |
| 150 | Elimination of visceral leishmaniasis on the Indian subcontinent. <i>Lancet Infectious Diseases</i> , <b>2016</b> , 16, e304-e309  | 25.5 | 78  |
| 149 | Novel Antigen Detection Assay to Monitor Therapeutic Efficacy of Visceral Leishmaniasis. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2016</b> , 95, 800-802  | 3.2  | 8   |
| 148 | Proteomic analyses of membrane enriched proteins of Leishmania donovani Indian clinical isolate by mass spectrometry. <i>Parasitology International</i> , <b>2015</b> , 64, 36-42  | 2.1  | 16  |
| 147 | Arsenic, antimony, and Leishmania: has arsenic contamination of drinking water in India led to treatment-resistant kala-azar?. <i>Lancet</i> , <b>2015</b> , 385 Suppl 1, S80  | 4.0  | 18  |
| 146 | Long-lasting insecticidal nets to prevent visceral leishmaniasis in the Indian subcontinent; methodological lessons learned from a cluster randomised controlled trial. <i>PLoS Neglected Tropical Diseases</i> , <b>2015</b> , 9, e0003597  | 4.8  | 12  |
| 145 | Arsenic exposure and outcomes of antimonial treatment in visceral leishmaniasis patients in Bihar, India: a retrospective cohort study. <i>PLoS Neglected Tropical Diseases</i> , <b>2015</b> , 9, e0003518  | 4.8  | 30  |
| 144 | In vitro and in vivo evaluation of anti-leishmanial and immunomodulatory activity of Neem leaf extract in Leishmania donovani infection. <i>Experimental Parasitology</i> , <b>2015</b> , 153, 45-54   | 2.1  | 24  |
| 143 | Antimony-Resistant Leishmania donovani Exploits miR-466i To Deactivate Host MyD88 for Regulating IL-10/IL-12 Levels during Early Hours of Infection. <i>Journal of Immunology</i> , <b>2015</b> , 195, 2731-42   | 5.3  | 23  |
| 142 | Developing imidazole analogues as potential inhibitor for Leishmania donovani trypanothione reductase: virtual screening, molecular docking, dynamics and ADMET approach. <i>Journal of Biomolecular Structure and Dynamics</i> , <b>2015</b> , 33, 2541-53                          | 3.6  | 34  |
| 141 | Single-dose indigenous liposomal amphotericin B in the treatment of Indian visceral leishmaniasis: a phase 2 study. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2015</b> , 92, 513-7   | 3.2  | 34  |
| 140 | Investigational drugs for visceral leishmaniasis. <i>Expert Opinion on Investigational Drugs</i> , <b>2015</b> , 24, 43-59   | 5.9  | 38  |
| 139 | An update on pharmacotherapy for leishmaniasis. <i>Expert Opinion on Pharmacotherapy</i> , <b>2015</b> , 16, 237-52  | 4    | 171 |
| 138 | Immunological consequences of stress-related proteins--cytosolic trypanothione peroxidase and chaperonin TCP20--identified in splenic amastigotes of Leishmania donovani as Th1 stimulatory, in experimental visceral leishmaniasis. <i>Parasitology</i> , <b>2015</b> , 142, 728-44 | 2.7  | 4   |

|     |  |      |    |
|-----|--|------|----|
| 137 | Outcome of patients on second line antiretroviral therapy under programmatic condition in India. <i>BMC Infectious Diseases</i> , <b>2015</b> , 15, 517  | 4    | 23 |
| 136 | Heterogeneity of <i>Leishmania donovani</i> parasites complicates diagnosis of visceral leishmaniasis: comparison of different serological tests in three endemic regions. <i>PLoS ONE</i> , <b>2015</b> , 10, e0116408  | 3.7  | 42 |
| 135 | Efficacy and safety of miltefosine in treatment of post-kala-azar dermal leishmaniasis. <i>Scientific World Journal, The</i> , <b>2015</b> , 2015, 414378  | 2.2  | 27 |
| 134 | Developments in Diagnosis of Visceral Leishmaniasis in the Elimination Era. <i>Journal of Parasitology Research</i> , <b>2015</b> , 2015, 239469   | 1.9  | 50 |
| 133 | Over-Expression of Cysteine Leucine Rich Protein Is Related to SAG Resistance in Clinical Isolates of <i>Leishmania donovani</i> . <i>PLoS Neglected Tropical Diseases</i> , <b>2015</b> , 9, e0003992   | 4.8  | 9  |
| 132 | Morphological and Genotypic Variations among the Species of the Subgenus <i>Adlerius</i> (Diptera: Psychodidae, Phlebotomus) in Iran. <i>Journal of Arthropod-Borne Diseases</i> , <b>2015</b> , 9, 84-97  | 0.8  | 11 |
| 131 | Visceral leishmaniasis. <i>Tropical Parasitology</i> , <b>2015</b> , 5, 83-5   | 0.4  | 15 |
| 130 | Parasite load estimation by qPCR differentiates between asymptomatic and symptomatic infection in Indian visceral leishmaniasis. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2014</b> , 80, 40-2  | 2.9  | 27 |
| 129 | Elucidation of cellular mechanisms involved in experimental paromomycin resistance in <i>Leishmania donovani</i> . <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 2580-5   | 5.9  | 54 |
| 128 | Whole blood assay and visceral leishmaniasis: Challenges and promises. <i>Immunobiology</i> , <b>2014</b> , 219, 323-8   | 3.4  | 17 |
| 127 | Characterization of the proliferating cell nuclear antigen of <i>Leishmania donovani</i> clinical isolates and its association with antimony resistance. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 2997-3007  | 5.9  | 13 |
| 126 | Imipramine exploits histone deacetylase 11 to increase the IL-12/IL-10 ratio in macrophages infected with antimony-resistant <i>Leishmania donovani</i> and clears organ parasites in experimental infection. <i>Journal of Immunology</i> , <b>2014</b> , 193, 4083-94                  | 5.3  | 25 |
| 125 | CD8 T cell exhaustion in human visceral leishmaniasis. <i>Journal of Infectious Diseases</i> , <b>2014</b> , 209, 290-9  | 7    | 91 |
| 124 | Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study. <i>The Lancet Global Health</i> , <b>2014</b> , 2, e51-7   | 13.6 | 51 |
| 123 | Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia. <i>PLoS ONE</i> , <b>2014</b> , 9, e100220   | 3.7  | 55 |
| 122 | Characterization of glycolytic enzymes--rAldolase and rEnolase of <i>Leishmania donovani</i> , identified as Th1 stimulatory proteins, for their immunogenicity and immunoprophylactic efficacies against experimental visceral leishmaniasis. <i>PLoS ONE</i> , <b>2014</b> , 9, e86073 | 3.7  | 36 |
| 121 | Exposure to <i>Phlebotomus argentipes</i> (Diptera, Psychodidae, Phlebotominae) sand flies in rural areas of Bihar, India: the role of housing conditions. <i>PLoS ONE</i> , <b>2014</b> , 9, e106771  | 3.7  | 18 |
| 120 | Association of interleukin-18 gene polymorphism with susceptibility to visceral leishmaniasis in endemic area of Bihar, an Indian population. <i>Scientific World Journal, The</i> , <b>2014</b> , 2014, 852104  | 2.2  | 5  |

|     |  |      |     |
|-----|--|------|-----|
| 119 | Comparative proteomics and glycoproteomics of plasma proteins in Indian visceral leishmaniasis. <i>Proteome Science</i> , <b>2014</b> , 12, 48   | 2.6  | 20  |
| 118 | Significantly lower anti-Leishmania IgG responses in Sudanese versus Indian visceral leishmaniasis. <i>PLoS Neglected Tropical Diseases</i> , <b>2014</b> , 8, e2675   | 4.8  | 28  |
| 117 | Model-based investigations of different vector-related intervention strategies to eliminate visceral leishmaniasis on the Indian subcontinent. <i>PLoS Neglected Tropical Diseases</i> , <b>2014</b> , 8, e2810  | 4.8  | 34  |
| 116 | Antimony resistant <i>Leishmania donovani</i> but not sensitive ones drives greater frequency of potent T-regulatory cells upon interaction with human PBMCs: role of IL-10 and TGF- $\beta$ in early immune response. <i>PLoS Neglected Tropical Diseases</i> , <b>2014</b> , 8, e2995            | 4.8  | 21  |
| 115 | <i>Leishmania</i> specific CD4 T cells release IFN- $\gamma$ that limits parasite replication in patients with visceral leishmaniasis. <i>PLoS Neglected Tropical Diseases</i> , <b>2014</b> , 8, e3198  | 4.8  | 46  |
| 114 | Quantitative PCR in epidemiology for early detection of visceral leishmaniasis cases in India. <i>PLoS Neglected Tropical Diseases</i> , <b>2014</b> , 8, e3366  | 4.8  | 33  |
| 113 | Efficacy and Safety of Paromomycin in Treatment of Post-Kala-Azar Dermal Leishmaniasis. <i>ISRN Parasitology</i> , <b>2014</b> , 2014, 548010  |      | 8   |
| 112 | Strong association between serological status and probability of progression to clinical visceral leishmaniasis in prospective cohort studies in India and Nepal. <i>PLoS Neglected Tropical Diseases</i> , <b>2014</b> , 8, e2657   | 4.8  | 53  |
| 111 | IgG1 as a potential biomarker of post-chemotherapeutic relapse in visceral leishmaniasis, and adaptation to a rapid diagnostic test. <i>PLoS Neglected Tropical Diseases</i> , <b>2014</b> , 8, e3273  | 4.8  | 36  |
| 110 | Efficacy and safety of amphotericin B emulsion versus liposomal formulation in Indian patients with visceral leishmaniasis: a randomized, open-label study. <i>PLoS Neglected Tropical Diseases</i> , <b>2014</b> , 8, e3169   | 4.8  | 35  |
| 109 | Immunotherapy and targeted therapies in treatment of visceral leishmaniasis: current status and future prospects. <i>Frontiers in Immunology</i> , <b>2014</b> , 5, 296  | 8.4  | 61  |
| 108 | Strategies to overcome antileishmanial drugs unresponsiveness. <i>Journal of Tropical Medicine</i> , <b>2014</b> , 2014, 646932  | 2.4  | 33  |
| 107 | Asymptomatic <i>Leishmania</i> infection: a new challenge for <i>Leishmania</i> control. <i>Clinical Infectious Diseases</i> , <b>2014</b> , 58, 1424-9  | 11.6 | 107 |
| 106 | Health & Demographic Surveillance System profile: the Muzaffarpur-TMRC Health and Demographic Surveillance System. <i>International Journal of Epidemiology</i> , <b>2014</b> , 43, 1450-7   | 7.8  | 8   |
| 105 | Nucleosomal histone proteins of <i>L. donovani</i> : a combination of recombinant H2A, H2B, H3 and H4 proteins were highly immunogenic and offered optimum prophylactic efficacy against <i>Leishmania</i> challenge in hamsters. <i>PLoS ONE</i> , <b>2014</b> , 9, e97911                        | 3.7  | 18  |
| 104 | Th1 stimulatory proteins of <i>Leishmania donovani</i> : comparative cellular and protective responses of rTriose phosphate isomerase, rProtein disulfide isomerase and rElongation factor-2 in combination with rHSP70 against visceral leishmaniasis. <i>PLoS ONE</i> , <b>2014</b> , 9, e108556 | 3.7  | 19  |
| 103 | Study the drug adherence and possible factor influencing drug adherence in HIV/AIDS patients in north eastern part of India. <i>Journal of Education and Health Promotion</i> , <b>2014</b> , 3, 31  | 1.4  | 3   |
| 102 | Characterization and evaluation of amine-modified graphene amphotericin B for the treatment of visceral leishmaniasis: in vivo and in vitro studies. <i>Drug Design, Development and Therapy</i> , <b>2014</b> , 8, 1235-47  | 4.4  | 12  |

|     |  |      |     |
|-----|--|------|-----|
| 101 | Leishmaniasis: an update of current pharmacotherapy. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 53-63  | 4    | 183 |
| 100 | Common variants in the HLA-DRB1-HLA-DQA1 HLA class II region are associated with susceptibility to visceral leishmaniasis. <i>Nature Genetics</i> , <b>2013</b> , 45, 208-13   | 36.3 | 76  |
| 99  | Oral miltefosine for Indian post-kala-azar dermal leishmaniasis: a randomised trial. <i>Tropical Medicine and International Health</i> , <b>2013</b> , 18, 96-100  | 2.3  | 37  |
| 98  | Latent infection with <i>Leishmania donovani</i> in highly endemic villages in Bihar, India. <i>PLoS Neglected Tropical Diseases</i> , <b>2013</b> , 7, e2053  | 4.8  | 43  |
| 97  | Seasonal variation in the prevalence of sand flies infected with <i>Leishmania donovani</i> . <i>PLoS ONE</i> , <b>2013</b> , 8, e61370  | 3.7  | 27  |
| 96  | Cloning, Expression and Purification of Specific Antigen for Serodiagnosis of Visceral Leishmaniasis. <i>Journal of Molecular Biomarkers &amp; Diagnosis</i> , <b>2013</b> , 4, 1000141  | 2    | 3   |
| 95  | Clinical profile and response to first-line ARV in HIV patients from Eastern UP and Bihar: a retrospective study. <i>Journal of the Association of Physicians of India, The</i> , <b>2013</b> , 61, 239-43   | 0.4  | 1   |
| 94  | A novel recombinant <i>Leishmania donovani</i> p45, a partial coding region of methionine aminopeptidase, generates protective immunity by inducing a Th1 stimulatory response against experimental visceral leishmaniasis. <i>International Journal for Parasitology</i> , <b>2012</b> , 42, 429-35 | 4.3  | 20  |
| 93  | Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India. <i>Tropical Medicine and International Health</i> , <b>2012</b> , 17, 1345-8  | 2.3  | 21  |
| 92  | Genetic markers for SSG resistance in <i>Leishmania donovani</i> and SSG treatment failure in visceral leishmaniasis patients of the Indian subcontinent. <i>Journal of Infectious Diseases</i> , <b>2012</b> , 206, 752-5   | 7    | 21  |
| 91  | Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. <i>Clinical Infectious Diseases</i> , <b>2012</b> , 55, 543-50  | 11.6 | 198 |
| 90  | Drug targeting to infectious diseases by nanoparticles surface functionalized with special biomolecules. <i>Current Medicinal Chemistry</i> , <b>2012</b> , 19, 3196-202   | 4.3  | 36  |
| 89  | Evaluation of <i>Leishmania donovani</i> protein disulfide isomerase as a potential immunogenic protein/vaccine candidate against visceral Leishmaniasis. <i>PLoS ONE</i> , <b>2012</b> , 7, e35670  | 3.7  | 34  |
| 88  | Visceral leishmaniasis in rural bihar, India. <i>Emerging Infectious Diseases</i> , <b>2012</b> , 18, 1662-4   | 10.2 | 35  |
| 87  | Molecular Docking and in Vitro Antileishmanial Evaluation of Chromene-2-thione Analogues. <i>ACS Medicinal Chemistry Letters</i> , <b>2012</b> , 3, 243-7  | 4.3  | 44  |
| 86  | Cytokine responses to novel antigens in an Indian population living in an area endemic for visceral leishmaniasis. <i>PLoS Neglected Tropical Diseases</i> , <b>2012</b> , 6, e1874  | 4.8  | 49  |
| 85  | Drug susceptibility in <i>Leishmania</i> isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis. <i>PLoS Neglected Tropical Diseases</i> , <b>2012</b> , 6, e1657   | 4.8  | 86  |
| 84  | Prevalence of sand flies and <i>Leishmania donovani</i> infection in a natural population of female <i>Phlebotomus argentipes</i> in Bihar State, India. <i>Vector-Borne and Zoonotic Diseases</i> , <b>2012</b> , 12, 467-72  | 2.4  | 13  |

|    |  |     |     |
|----|--|-----|-----|
| 83 | Reassessment of immune correlates in human visceral leishmaniasis as defined by cytokine release in whole blood. <i>Vaccine Journal</i> , <b>2012</b> , 19, 961-6  |     | 79  |
| 82 | Post-kala-azar dermal leishmaniasis (PKDL) in visceral leishmaniasis-endemic communities in Bihar, India. <i>Tropical Medicine and International Health</i> , <b>2012</b> ,  | 2.3 | 9   |
| 81 | <i>Leishmania donovani</i> : immunostimulatory cellular responses of membrane and soluble protein fractions of splenic amastigotes in cured patient and hamsters. <i>PLoS ONE</i> , <b>2012</b> , 7, e30746  | 3.7 | 5   |
| 80 | Recent advances in the diagnosis and treatment of kala-azar. <i>The National Medical Journal of India</i> , <b>2012</b> , 25, 85-9   | 0.4 | 21  |
| 79 | A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. <i>Vaccine</i> , <b>2011</b> , 29, 3531-7   | 4.1 | 111 |
| 78 | Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. <i>Lancet, The</i> , <b>2011</b> , 377, 477-86  | 4.0 | 245 |
| 77 | Phase 4 pharmacovigilance trial of paromomycin injection for the treatment of visceral leishmaniasis in India. <i>Journal of Tropical Medicine</i> , <b>2011</b> , 2011, 645203  | 2.4 | 31  |
| 76 | Visceral leishmaniasis in Muzaffarpur district, Bihar, India from 1990 to 2008. <i>PLoS ONE</i> , <b>2011</b> , 6, e14751  | 3.7 | 37  |
| 75 | Nano-structured nickel oxide based DNA biosensor for detection of visceral leishmaniasis (Kala-azar). <i>Analyst, The</i> , <b>2011</b> , 136, 2845-51   | 5   | 62  |
| 74 | Ambisome plus miltefosine for Indian patients with kala-azar. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , <b>2011</b> , 105, 115-7   | 2   | 26  |
| 73 | Pharmacokinetics of oral sitamaquine taken with or without food and safety and efficacy for treatment of visceral leishmaniasis: a randomized study in Bihar, India. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2011</b> , 84, 892-900  | 3.2 | 18  |
| 72 | Serial quantitative PCR assay for detection, species discrimination, and quantification of <i>Leishmania</i> spp. in human samples. <i>Journal of Clinical Microbiology</i> , <b>2011</b> , 49, 3892-904   | 9.7 | 128 |
| 71 | Elongation factor-2, a Th1 stimulatory protein of <i>Leishmania donovani</i> , generates strong IFN- $\gamma$ and IL-12 response in cured <i>Leishmania</i> -infected patients/hamsters and protects hamsters against <i>Leishmania</i> challenge. <i>Journal of Immunology</i> , <b>2011</b> , 187, 6417-27 | 5.3 | 55  |
| 70 | IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis. <i>Journal of Immunology</i> , <b>2011</b> , 186, 3977-85  | 5.3 | 115 |
| 69 | Whole genome sequencing of multiple <i>Leishmania donovani</i> clinical isolates provides insights into population structure and mechanisms of drug resistance. <i>Genome Research</i> , <b>2011</b> , 21, 2143-56   | 9.7 | 319 |
| 68 | Visceral leishmaniasis in the Indian subcontinent: modelling epidemiology and control. <i>PLoS Neglected Tropical Diseases</i> , <b>2011</b> , 5, e1405  | 4.8 | 125 |
| 67 | Incidence of symptomatic and asymptomatic <i>Leishmania donovani</i> infections in high-endemic foci in India and Nepal: a prospective study. <i>PLoS Neglected Tropical Diseases</i> , <b>2011</b> , 5, e1284   | 4.8 | 118 |
| 66 | Interferon-gamma release assay (modified QuantiFERON) as a potential marker of infection for <i>Leishmania donovani</i> , a proof of concept study. <i>PLoS Neglected Tropical Diseases</i> , <b>2011</b> , 5, e1042   | 4.8 | 42  |

|    |   |      |      |
|----|---|------|------|
| 65 | IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis. <i>Journal of Infectious Diseases</i> , <b>2011</b> , 204, 1134-7   | 7    | 128  |
| 64 | Diagnosis of Indian visceral leishmaniasis by nucleic acid detection using PCR. <i>PLoS ONE</i> , <b>2011</b> , 6, e19304   | 3.7  | 52   |
| 63 | Liposomal amphotericin B and leishmaniasis: dose and response. <i>Journal of Global Infectious Diseases</i> , <b>2010</b> , 2, 159-66   | 2.8  | 103  |
| 62 | Evaluation of blood agar microtiter plates for culturing leishmania parasites to titrate parasite burden in spleen and peripheral blood of patients with visceral leishmaniasis. <i>Journal of Clinical Microbiology</i> , <b>2010</b> , 48, 1932-4 | 9.7  | 35   |
| 61 | Longlasting insecticidal nets for prevention of Leishmania donovani infection in India and Nepal: paired cluster randomised trial. <i>BMJ, The</i> , <b>2010</b> , 341, c6760   | 5.9  | 80   |
| 60 | Antimony toxicity. <i>International Journal of Environmental Research and Public Health</i> , <b>2010</b> , 7, 4267-77  | 4.6  | 353  |
| 59 | Evaluation of ex vivo human immune response against candidate antigens for a visceral leishmaniasis vaccine. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2010</b> , 82, 808-13  | 3.2  | 27   |
| 58 | Amplified fragment length polymorphism (AFLP) analysis is useful for distinguishing Leishmania species of visceral and cutaneous forms. <i>Acta Tropica</i> , <b>2010</b> , 113, 202-6  | 3.2  | 23   |
| 57 | Single-dose liposomal amphotericin B for visceral leishmaniasis in India. <i>New England Journal of Medicine</i> , <b>2010</b> , 362, 504-12  | 59.2 | 299  |
| 56 | Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment. <i>Clinical Infectious Diseases</i> , <b>2009</b> , 49, 914-8  | 11.6 | 38   |
| 55 | Longitudinal Seroepidemiologic Study of Visceral Leishmaniasis in Hyperendemic Regions of Bihar, India. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2009</b> , 80, 345-346  | 3.2  | 32   |
| 54 | Longitudinal seroepidemiologic study of visceral leishmaniasis in hyperendemic regions of Bihar, India. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2009</b> , 80, 345-6  | 3.2  | 29   |
| 53 | Induction of Th1-type cellular responses in cured/exposed Leishmania-infected patients and hamsters against polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa. <i>Vaccine</i> , <b>2008</b> , 26, 4813-8      | 4.1  | 29   |
| 52 | Paromomycin in the treatment of leishmaniasis. <i>Expert Opinion on Investigational Drugs</i> , <b>2008</b> , 17, 787-94  | 5.9  | 66   |
| 51 | New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. <i>Clinical Infectious Diseases</i> , <b>2008</b> , 47, 1000-6   | 11.6 | 158  |
| 50 | Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. <i>Journal of Infectious Diseases</i> , <b>2007</b> , 196, 591-8   | 7    | 194  |
| 49 | Injectable paromomycin for Visceral leishmaniasis in India. <i>New England Journal of Medicine</i> , <b>2007</b> , 356, 2571-81   | 59.2 | 312  |
| 48 | Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?. <i>Nature Reviews Microbiology</i> , <b>2007</b> , 5, 873-82  | 22.2 | 1047 |

|    |  |      |      |
|----|--|------|------|
| 47 | Evaluation of rapid diagnostic tests: visceral leishmaniasis. <i>Nature Reviews Microbiology</i> , <b>2007</b> , 5, S31-S39  | 2.2  | 67   |
| 46 | Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions. <i>Clinical Infectious Diseases</i> , <b>2007</b> , 45, 556-61  | 11.6 | 66   |
| 45 | Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis. <i>Journal of Experimental Medicine</i> , <b>2007</b> , 204, 805-17                                | 16.6 | 260  |
| 44 | Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?. <i>Nature Reviews Microbiology</i> , <b>2007</b> , 5, S7-S16   | 22.2 | 35   |
| 43 | Rapid, noninvasive diagnosis of visceral leishmaniasis in India: comparison of two immunochromatographic strip tests for detection of anti-K39 antibody. <i>Journal of Clinical Microbiology</i> , <b>2006</b> , 44, 251-3           | 9.7  | 68   |
| 42 | Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis. <i>Clinical Infectious Diseases</i> , <b>2006</b> , 42, 608-13   | 11.6 | 22   |
| 41 | Drug resistance in leishmaniasis. <i>Clinical Microbiology Reviews</i> , <b>2006</b> , 19, 111-26  | 34   | 1183 |
| 40 | Comparative evaluation of freeze-dried and liquid antigens in the direct agglutination test for serodiagnosis of visceral leishmaniasis (ITMA-DAT/VL). <i>Tropical Medicine and International Health</i> , <b>2006</b> , 11, 1777-84 | 2.3  | 39   |
| 39 | Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , <b>2006</b> , 100, 698-700                               | 2    | 25   |
| 38 | Oral miltefosine for the treatment of Indian visceral leishmaniasis. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , <b>2006</b> , 100 Suppl 1, S26-33   | 2    | 77   |
| 37 | KNOWLEDGE, ATTITUDE, AND PRACTICES RELATED TO KALA-AZAR IN A RURAL AREA OF BIHAR STATE, INDIA. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2006</b> , 75, 505-508  | 3.2  | 39   |
| 36 | Knowledge, attitude, and practices related to Kala-azar in a rural area of Bihar state, India. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2006</b> , 75, 505-8  | 3.2  | 29   |
| 35 | Treatment of visceral leishmaniasis. <i>Expert Opinion on Pharmacotherapy</i> , <b>2005</b> , 6, 2821-9  | 4    | 70   |
| 34 | Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models. <i>Parasitology Research</i> , <b>2005</b> , 96, 216-23                             | 2.4  | 101  |
| 33 | Availability of miltefosine for the treatment of kala-azar in India. <i>Bulletin of the World Health Organization</i> , <b>2005</b> , 83, 394-5  | 8.2  | 79   |
| 32 | A PHASE II DOSE-RANGING STUDY OF SITAMAQUINE FOR THE TREATMENT OF VISCERAL LEISHMANIASIS IN INDIA. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2005</b> , 73, 1005-1011  | 3.2  | 78   |
| 31 | DETECTION OF LEISHMANIAL ANTIGEN IN THE URINE OF PATIENTS WITH VISCERAL LEISHMANIASIS BY A LATEX AGGLUTINATION TEST. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2005</b> , 73, 269-271                            | 3.2  | 53   |
| 30 | VIRGIN SOIL: THE SPREAD OF VISCERAL LEISHMANIASIS INTO UTTAR PRADESH, INDIA. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2005</b> , 73, 720-725  | 3.2  | 50   |

|    |   |      |     |
|----|---|------|-----|
| 29 | Detection of leishmanial antigen in the urine of patients with visceral leishmaniasis by a latex agglutination test. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2005</b> , 73, 269-71                          | 3.2  | 27  |
| 28 | Virgin soil: the spread of visceral leishmaniasis into Uttar Pradesh, India. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2005</b> , 73, 720-5   | 3.2  | 39  |
| 27 | A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2005</b> , 73, 1005-11   | 3.2  | 30  |
| 26 | Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. <i>Clinical Infectious Diseases</i> , <b>2004</b> , 38, 377-83  | 11.6 | 141 |
| 25 | Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis. <i>Pediatric Infectious Disease Journal</i> , <b>2003</b> , 22, 434-8   | 3.4  | 61  |
| 24 | Diagnosis and treatment of Indian visceral leishmaniasis. <i>Journal of the Association of Physicians of India, The</i> , <b>2003</b> , 51, 195-201   | 0.4  | 12  |
| 23 | Laboratory diagnosis of visceral leishmaniasis. <i>Vaccine Journal</i> , <b>2002</b> , 9, 951-8   |      | 180 |
| 22 | Advances in the treatment of leishmaniasis. <i>Current Opinion in Infectious Diseases</i> , <b>2002</b> , 15, 593-8   | 5.4  | 92  |
| 21 | Oral miltefosine for Indian visceral leishmaniasis. <i>New England Journal of Medicine</i> , <b>2002</b> , 347, 1739-46   | 59.2 | 543 |
| 20 | NADH-oxidase, NADPH-oxidase and myeloperoxidase activity of visceral leishmaniasis patients. <i>Journal of Medical Microbiology</i> , <b>2002</b> , 51, 832-836   | 3.2  | 41  |
| 19 | Treatment of visceral leishmaniasis. <i>Medical Microbiology and Immunology</i> , <b>2001</b> , 190, 89-92  | 4    | 39  |
| 18 | Drug resistance in Indian visceral leishmaniasis. <i>Tropical Medicine and International Health</i> , <b>2001</b> , 6, 849-54   | 3    | 443 |
| 17 | Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. <i>BMJ: British Medical Journal</i> , <b>2001</b> , 323, 419-22                                 |      | 120 |
| 16 | Short-course of oral miltefosine for treatment of visceral leishmaniasis. <i>Clinical Infectious Diseases</i> , <b>2000</b> , 31, 1110-3  | 11.6 | 120 |
| 15 | Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. <i>Clinical Infectious Diseases</i> , <b>2000</b> , 31, 1104-7   | 11.6 | 499 |
| 14 | Diagnostic PCR with <i>Leishmania donovani</i> specificity using sequences from the variable region of kinetoplast minicircle DNA. <i>Tropical Medicine and International Health</i> , <b>1999</b> , 4, 448-53                    | 2.3  | 20  |
| 13 | Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. <i>New England Journal of Medicine</i> , <b>1999</b> , 341, 1795-800  | 59.2 | 377 |
| 12 | Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of <i>Leishmania donovani</i> . <i>Journal of Infectious Diseases</i> , <b>1999</b> , 180, 564-7 | 7    | 287 |

|    |   |     |     |
|----|---|-----|-----|
| 11 | Diagnostic and prognostic potential of a competitive enzyme-linked immunosorbent assay for leishmaniasis in India. <i>Vaccine Journal</i> , <b>1999</b> , 6, 550-4                                      |     | 13  |
| 10 | Trial of oral miltefosine for visceral leishmaniasis. <i>Lancet, The</i> , <b>1998</b> , 352, 1821-3  | 40  | 205 |
| 9  | Splenic cytokine responses in Indian kala-azar before and after treatment. <i>Journal of Infectious Diseases</i> , <b>1998</b> , 177, 815-8   | 7   | 113 |
| 8  | Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis. <i>Journal of Infectious Diseases</i> , <b>1997</b> , 176, 1117-9  | 7   | 93  |
| 7  | Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. <i>Annals of Internal Medicine</i> , <b>1997</b> , 127, 133-7                          | 8   | 71  |
| 6  | Molecular typing of HLA class I and class II antigens in Indian kala-azar patients. <i>Tropical Medicine and International Health</i> , <b>1997</b> , 2, 468-471  | 2.3 | 19  |
| 5  | Circulating T helper 1 (Th1) cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>1997</b> , 56, 522-5 | 3.2 | 103 |
| 4  | Failure of ketoconazole treatment in cutaneous leishmaniasis. <i>International Journal of Dermatology</i> , <b>1995</b> , 34, 120-1   | 1.7 | 14  |
| 3  | Immunochemotherapy for a systemic intracellular infection: accelerated response using interferon-gamma in visceral leishmaniasis. <i>Journal of Infectious Diseases</i> , <b>1995</b> , 171, 992-6      | 7   | 67  |
| 2  | Evaluation of the direct agglutination test as an immunodiagnostic tool for kala-azar in India. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , <b>1993</b> , 87, 276-8     | 2   | 31  |
| 1  | Four layer multi-omics reveals molecular responses to aneuploidy in Leishmania  |     | 1   |